Single-cell transcriptomics reveals a complex cell-cell communication network driven by myofibroblast-derived collagen in esophageal squamous cell carcinoma.
Sep 2026· Cancer Letters· pp.
218839
· 0 citations· 108 references
Medicine
TL;DR
A high-resolution single-cell transcriptomic atlas of the ESCC tumor microenvironment is constructed via single-cell RNA sequencing of 15 tissue specimens derived from 8 ESCC patients, revealing Fibro_myo_C1 as a prominent fibroblast subset associated with ESCC progression that orchestrates stromal crosstalk to drive malignancy, angiogenesis, and immune suppression.
Abstract
Fibroblasts are pivotal regulators of tumor development, progression, and therapeutic resistance in human malignancies. However, their functional diversity and cellular heterogeneity in esophageal squamous cell carcinoma (ESCC) remain largely elusive. In the present study, we constructed a high-resolution single-cell transcriptomic atlas of the ESCC tumor microenvironment (TME) via single-cell RNA sequencing of 15 tissue specimens derived from 8 ESCC patients. A distinct collagen-synthesizing myofibroblast subpopulation, termed Fibro_myo_C1, was identified as a potentially important fibroblast subset driving ESCC progression. This subset exhibited robust expression of collagen- and fibronectin-encoding genes including COL1A1, COL1A2, COL3A1, and FN1. Functionally, Fibro_myo_C1 might promote epithelial-mesenchymal transition in malignant cells, enhance angiogenesis in endothelial cells, and induce an immunosuppressive TME by recruiting Tregs, exhausting CD8+ T cells, and polarizing M2-like macrophages. Clinically, high infiltration of Fibro_myo_C1 was significantly correlated with poor neoadjuvant immunotherapy response in ESCC patients. In conclusion, our study reveals Fibro_myo_C1 as a prominent fibroblast subset associated with ESCC progression that orchestrates stromal crosstalk to drive malignancy, angiogenesis, and immune suppression. Targeting Fibro_myo_C1 may represent a promising therapeutic strategy to reverse immunotherapy resistance and improve clinical outcomes for ESCC patients.
These findings identify a tumor-adapted MC state that orchestrates immune evasion and tissue remodeling during CRC progression, supporting the notion that MC are reprogrammed toward an immune-suppressive and pro-tumorigenic phenotype.
E. Putro, Alessia Carnevale, Caterina Marangio et al.· Cell Death & Disease· 0 citations
Integrative single-cell RNA sequencing analysis of publicly available datasets from non-small cell lung cancer and breast cancer is performed to systematically map transcriptional heterogeneity and regulatory networks within the TME, providing a systems-level framework of TME organization.
M. O. Odubote, Chiemeka Elochi Emeribe· bioRxiv· 0 citations
An HDGF/ENO1/H4K12la/iCAF axis that links tumor metabolic reprogramming, stromal inflammatory activation, and immunosuppression in ESCC is revealed, identifying this axis as a promising therapeutic target for overcoming immunotherapy resistance.
Zhengqing Song, Cai-Nan Li, Pujie Wu et al.· Cancer Letters· 0 citations
Findings indicate that glycolytic heterogeneity is a key feature of CRC malignant epithelial cells and is closely associated with tumor progression, microenvironmental remodeling, and clinical outcomes.
Jin-Yu Xiao, Shan-Shan Heng, Jia-Yu Li et al.· Functional & Integrative Gen...· 0 citations
It is suggested that C7 fibroblasts being predominantly distributed in tumor‐adjacent normal tissues is significantly associated with cervical cancer progression, and that C7 fibroblasts in these tissues may serve as potential biomarkers and therapeutic targets for tumor microenvironment modulation.
Yi Liu, D. Yin, Lu-guang Wu et al.· Frontiers in Cell and Develo...· 0 citations
This study suggests that MCs are key orchestrators of immunosuppression in PDAC, predicted to interact with Tregs through the MIF–CD74/CXCR4 axis, offering a novel rationale for targeting the MC–Treg axis in future immunotherapeutic strategies.
Mengli Wu, Xuxia Ye, Qi Yu et al.· Annals medicus· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.